Efficacy and safety of surufatinib, a novel dual-mechanism inhibitor, as a second-line or further treatment in advanced sarcoma: a multicenter, single-arm, phase 2 trial
Authors: Xu, Bushu; Pan, Qiuzhong; Li, Shining; Peng, Ruiqing; Zhang, Lihong; Li, Hui; Yu, Shiying; Zhang, Xing
Source journal: BMC medicine (2026-08-25)
DOI: 10.1186/s12916-026-05154-7
Abstract
BACKGROUND: Patients with advanced, treatment-refractory sarcoma face a poor prognosis and limited options following failure of standard therapies. This study evaluated the efficacy and safety of surufatinib, a novel inhibitor targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and colony-stimulating factor-1 receptor (CSF-1R), in patients with advanced sarcoma who had failed standard therapy. METHODS: In this multicenter, single-arm, phase 2 trial, patients with unresectable or metastatic sarcoma who had received prior treatment were enrolled and received surufatinib 300 mg once daily. The primary endpoint was the 12-week progression-free rate (PFR(12w)). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). RESULTS: As of September 30, 2025, the median follow-up was 27.5 months among 47 enrolled patients; 46.8% had received >/= 2 prior lines of therapy. In 45 evaluable patients, the PFR(12w) was 71.1%. The ORR was 11.1%, including one complete response in a patient with angiosarcoma, and the DCR was 86.7%. Median PFS was 4.3 months, with significantly longer PFS when surufatinib was used as second-line therapy compared with later lines (5.7 vs. 2.8 months; p /= 3 treatment-related adverse events occurred in 29.8% of patients. CONCLUSIONS: These findings indicate that surufatinib has preliminary antitumor activity and a manageable safety profile in advanced sarcoma, even after prior anti-angiogenic therapy. The encouraging efficacy observed in the second-line setting and in non-uterine leiomyosarcoma provides a rationale for continued clinical development. TRIAL REGISTRATION: ClinicalTrials.gov: NCT05106777. CLINICA TRIAL REGISTRY: ClinicalTrials.gov ( http://www. CLINICALTRIALS: gov/ ).
Related topics
Related open access articles
- N and K interactions in cucumber plants artificially inoculated with P. cubensis
- The impact of potassium on downy mildew of cucumber and its leaf/soil nutritional status.
- Impacts of Climate Change on Rural-Urban Migration and Agricultural Productivity in Southern Region of Kebbi State, Nigeria.
- Analysis of Greenhouse Gas (Methane and Nitrous Oxide) emission and global warming potential from rice fields: with reference to biological mitigation of climate change.
- Nitrogenous Fertilizers – Boon or Bane?
- Modeling of energy intensity in aquaculture: Future energy use of global aquaculture
Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.